Nogrady S G, Hartley J P, Handslip P D, Hurst N P
Thorax. 1978 Aug;33(4):479-82. doi: 10.1136/thx.33.4.479.
H1 receptor blocking antihistamines administered by mouth have not found a clear place in the management of bronchial asthma. We investigated the possibility that higher concentrations of these drugs, administered directly to the bronchial tree, might produce bronchodilatation. Twelve asthmatic patients inhaled aerosols generated from solutions of clemastine (0.05%), salbutamol (0.5%), and placebo. Bronchodilatation was assessed by changes in the forced expiratory volume in one second (FEV1) and peak expiratory flow rate (PEFR) over four hours. Both clemastine and salbutamol caused significant bronchodilatation. The mean maximum percentage increases in FEV1 for clemastine and salbutamol were 21.1% and 29.2% respectively. The mean maximum percentage increases in PEFR were 31.2% and 35.2% respectively. There was no significant difference in the maximum bronchodilatation produced by the two drugs. Clemastine, when administered by aerosol inhalation, appears to be an effective bronchodilator.
口服的H1受体阻断抗组胺药在支气管哮喘的治疗中尚未找到明确的应用地位。我们研究了将这些药物以更高浓度直接注入支气管树可能产生支气管扩张的可能性。12名哮喘患者吸入了由氯马斯汀（0.05%）、沙丁胺醇（0.5%）溶液及安慰剂产生的气雾剂。通过在4小时内一秒用力呼气量（FEV1）和呼气峰值流速（PEFR）的变化来评估支气管扩张情况。氯马斯汀和沙丁胺醇均引起了显著的支气管扩张。氯马斯汀和沙丁胺醇的FEV1平均最大百分比增加值分别为21.1%和29.2%。PEFR的平均最大百分比增加值分别为31.2%和35.2%。两种药物产生的最大支气管扩张效果无显著差异。通过气雾剂吸入给药时，氯马斯汀似乎是一种有效的支气管扩张剂。
